Effect of Filgotinib vs Placebo on Clinical Response in Patients with Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
JAMA 2019 322(4):315-325
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
JAMA 2019 322(4):315-325
Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215764
Lancet 2019;394:576–86. doi: 10.1016/S0140-6736(19)30952-3
Treatment with risankizumab showed significantly greater efficacy over adalimumab in providing substantial skin clearance in patients with moderate-to-severe chronic plaque PsO. This study aimed to assess the safety and efficacy of risankizumab compared with adalimumab in an active-comparator Phase 3 trial.
Arthritis Care and Research 2019 DOI: 10.1002/acr.24010
Ann Rheum Dis. 2019 Jul;78(7):890-898.
EULAR 2019 Abstract LB0003 Presentation
EULAR 2019 Abstract LB0001 Presentation
J Immunol 2019;202:2888–2906. DOI: 10.4049/jimmunol.1800583
Lancet. 2019 Jun 8;393(10188):2303-2311
Arthritis Res Ther. 2019 Apr 5;21(1):89.